Ray Dalio’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.1M Buy
+89,106
New +$14.5M 0.07% 269
2026
Q1
– Sell
-7,874
Closed -$1.29M – 1183
2025
Q4
$1.29M Sell
7,874
-25,742
-77% -$4.03M ﹤0.01% 845
2025
Q3
$4.49M Buy
+33,616
New +$4.08M 0.02% 514
2023
Q1
– Sell
-6,898
Closed -$1.17M – 862
2022
Q4
$1.17M Buy
6,898
+4,674
+210% +$848K 0.01% 625
2022
Q3
$416K Sell
2,224
-1,386
-38% -$292K ﹤0.01% 795
2022
Q2
$586K Buy
3,610
+618
+21% +$97.7K ﹤0.01% 883
2022
Q1
$563K Buy
+2,992
New +$568K ﹤0.01% 873
2021
Q4
– Sell
-736
Closed -$213K – 797
2021
Q3
$213K Buy
+736
New +$189K ﹤0.01% 673

Other funds holding RGEN

Ray Dalio's RGEN Position: Q3 2026 in Review

Ray Dalio opened a new position in Repligen (RGEN) in Q3 2026: 89,106 shares worth $17.1M. The stake represents 0.07% of the portfolio and ranks #269 among its holdings. This is a return to the name: Ray Dalio previously reported a position in RGEN as recently as Q4 2025.

Ray Dalio first reported a position in RGEN in Q3 2021 and has held it in 8 quarters since. 518 funds tracked by Wall St. Rank hold RGEN as of Q3 2026.

  • Ray Dalio held 89,106 shares of Repligen worth $17.1M as of Q3 2026.
  • Repligen was a new Ray Dalio position in Q3 2026.
  • Repligen made up 0.07% of Ray Dalio's portfolio in Q3 2026, its #269 holding.
  • Ray Dalio first reported a position in Repligen in Q3 2021 and has held it in 8 quarters since.
  • 518 funds tracked by Wall St. Rank held Repligen as of Q3 2026.

Based on Bridgewater Associates's 13F filing for Q3 2026, filed 16 Nov 2026.